CTMX: the balance sheet

MyFinsight

CytomX Therapeutics, Inc. (CTMX)

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	28,828	12,667	34,185	49,041
Short-term investments	317,879	124,385	109,441	109,046
Accounts receivable	646	2,013	1,629	1,869
Prepaid expenses and other current assets	5,743	4,856	3,962	4,665
Total current assets	353,096	143,921	149,217	164,621
Property and equipment, net	1,090	1,304	1,721	1,946
Intangible assets, net	401	438	474	510
Goodwill	949	949	949	949
Restricted cash	1,527	1,527	1,028	1,028
Operating lease right-of-use asset	2,264	3,396	4,814	5,947
Other assets	31	31	51	56
Total assets	359,358	151,566	158,254	175,057

Accounts payable	1,368	1,301	646	227
Accrued liabilities	11,923	14,197	12,408	11,503
Operating lease liabilities - short term	2,856	4,240	5,596	5,443
Deferred revenue, current portion	17,876	26,877	22,379	22,050
Operating lease liabilities - long term	NaN	0	0	1,442
Total current liabilities	34,023	46,615	41,029	39,223
Deferred revenue, net of current portion	979	1,590	5,537	10,241
Other long-term liabilities	4,412	4,353	4,299	4,241
Total liabilities	39,414	52,558	50,865	55,147
Convertible preferred stock	0	NaN	0	0
Common stock	2	2	2	2
Additional paid-in capital	1,050,037	810,844	789,720	788,083
Accumulated other comprehensive income	102	111	104	33
Accumulated deficit	-730,197	-711,949	-682,437	-668,208
Total stockholders' equity	319,944	99,008	107,389	119,910
Total liabilities and stockholders' equity	359,358	151,566	158,254	175,057

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.